Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-28

Mdxhealth Sa (MDXH) Stock Forecast Oct. 28, 2026

Analysis updated on Oct. 28, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Share
X LinkedIn Reddit WhatsApp Telegram
Embed badge
Unlock full AI forecasts
 This forecast was produced 5 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Rating · 90D NO CURRENT FORECAST Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage n/a Not ranked
Rank correlation · 90D 34.0% Spearman, 220 dates
Market Cap $18M small-cap · #22 of 26 peers
Summary

Mdxhealth Sa (MDXH) stock forecast summary

This forecast was produced 5 trading days ago and has not been refreshed since; read it as historical, not as a current view.

Mdxhealth Sa is a small-cap company with a market capitalization of $18M. It ranks number 22 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast.

For MDXH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 34.0%, measured on 220 forecast dates between 2025-04-02 and 2026-07-30 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 262 forecast dates between 2025-04-02 and 2026-09-28. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)

Price

MDXH price chart and AI forecast

MDXH
Cross-section · 2026-10-30

How MDXH ranks among 4891 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2024-12-31

Mdxhealth Sa (MDXH) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.

Valuation & Market

MetricMDXHIndustry medianRank
Market Cap $18M $1.46B 22/26

Dividend & Shareholder Information

MetricMDXHIndustry medianRank
Shares Outstanding 91M – –

Balance Sheet Highlights (USD millions)

Total Liabilities$142M
Quarterly Financial Reports

MDXH quarterly financials and insider trading

Industry Peers · Services-Medical Laboratories

Mdxhealth Sa (MDXH) industry peers

Companies classified under the same SEC industry code as Mdxhealth Sa (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
MDXH Mdxhealth Sa $18M – –
NTRA Natera, Inc. $54.62B – 30.0x
LH Labcorp Holdings Inc. $28.84B 29.2x 3.3x
DGX Quest Diagnostics Inc $27.18B 24.6x 3.6x
GH Guardant Health, Inc. $23.48B – –
CAI Caris Life Sciences, Inc. $9.70B 7.2x 16.4x
GRAL Grail, Inc. $6.23B – 2.5x
RDNT Radnet, Inc. $5.78B – 5.3x
BLLN Billiontoone, Inc. $5.21B 380.8x –
CDNA Caredx, Inc. $4.52B 43.9x 9.7x
VCYT Veracyte, Inc. $3.94B 43.0x 2.8x
CELC Celcuity Inc. $3.38B – –
FTRE Fortrea Holdings Inc. $2.02B – 3.8x
PSNL Personalis, Inc. $1.68B – 7.2x
FRNM Freenome, Inc. $1.23B – –
CSTL Castle Biosciences Inc $1.07B – 2.3x
LMRI Lumexa Imaging Holdings, Inc. $1.07B – 1.7x
FLGT Fulgent Genetics, Inc. $533M – 0.5x
BDSX Biodesix Inc $222M – 24.3x
XGN Exagen Inc. $203M – 16.6x
BNR Burning Rock Biotech Ltd $117M – 2.1x
SERA Sera Prognostics, Inc. $78M – 1.3x
AMS American Shared Hospital Services $8M – 0.4x
ACON Aclarion, Inc. $5M – 0.3x
ADVB Advanced Biomed Inc. $3M – 0.4x
BGLC Bionexus Gene Lab Corp $3M – 0.4x
RNLXY Renalytix Plc N/A – –

Where MDXH sits on the market map

Industrial Applications and Services · Services-Medical Laboratories
Explore the map →
News

Mdxhealth Sa (MDXH) stock news

Loading...

FAQ

Mdxhealth Sa (MDXH) stock forecast FAQ

What is the Mdxhealth Sa (MDXH) stock forecast?

This forecast was produced 5 trading days ago and has not been refreshed since; read it as historical, not as a current view.

How accurate are Mdxhealth Sa stock predictions?

For MDXH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 34.0%, measured on 220 forecast dates between 2025-04-02 and 2026-07-30 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 262 forecast dates between 2025-04-02 and 2026-09-28. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Mdxhealth Sa forecasts updated?

Mdxhealth Sa forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 28, 2026.

Which companies are Mdxhealth Sa's industry peers?

27 issuers in our coverage, MDXH included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.